Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18746321 | 0.86 | ATR (0.42) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL9589081 | 0.84 | L3MBTL1 (0.53) | MAPK1LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL29455017 | 0.84 | L3MBTL1 (0.53) | MAPK1LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2490163 | 0.83 | CFTR (0.48) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL24391507 | 0.83 | CFTR (0.49) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL16676253 | 0.81 | CFTR (0.55) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL16395600 | 0.81 | KMT2A (0.49) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL30173812 | 0.81 | CFTR (0.55) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL4188243 | 0.81 | NOTUM (0.49) | MAPK1LMNAGAACFTRKMT2A | |
| SCHEMBL1585179 | 0.80 | SORT1 (0.53) | MAPK1LMNAGAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12538924-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | SYNGENTA CROP PROTECTION AG (CH) | 2026-02-03 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| WO-2025090792-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-113811532-B | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达农作物保护股份公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12234247-B2 | Heterocyclic compound and harmful arthropod-controlling composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-02-25 | — | — | US | disclosed |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| WO-2014069510-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014053694-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORPORATION (FI) | 2014-04-10 | — | — | WO | disclosed |
| EP-2649061-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | MAPK1 1701/4885LMNA 2647/4885GAA 2552/4885 |
| US-12538924-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | CBR3, CBR1, CYCS | MAPK1 2200/4885LMNA 1604/4885GAA 2366/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | MAPK1 1705/4885LMNA 2318/4885GAA 2702/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | MAPK1 1311/4885LMNA 634/4885GAA 3944/4885 |
| US-12234231-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | MAPK1 1701/4885LMNA 2647/4885GAA 2552/4885 |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, CNR1 | MAPK1 413/4885LMNA 3278/4885GAA 4885/4885 |
| US-12234247-B2 | Heterocyclic compound and harmful arthropod-controlling composition containing same | C5, COX6C, COX6B1 | MAPK1 2396/4885LMNA 2209/4885GAA 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.